Prenatal Diagnosis and Management of Fetal Goiter: A Case Series from Tertiary Perinatal Center in South India

S. Vavilala, Manjula Budidapadu, G. Kolar
{"title":"Prenatal Diagnosis and Management of Fetal Goiter: A Case Series from Tertiary Perinatal Center in South India","authors":"S. Vavilala, Manjula Budidapadu, G. Kolar","doi":"10.5005/jp-journals-10016-1187","DOIUrl":null,"url":null,"abstract":"The reported incidence of fetal goiter is 1 in 40,000 live births. The effects of fetal goiter and thyroid dysfunction are significant. The objective of our study is to assess the safety, feasibility, and efficacy of intra-amniotic instillation of levothyroxine (LT4) in fetal goitrous hypothyroidism.\n\n\n\nA retrospective observational study of prenatally diagnosed cases of fetal goiter on routine antenatal ultrasound between January 2010 and January 2018 at Fernandez Hospital Foundation, Hyderabad, tertiary perinatal referral center. Data retrieved from electronic database.\n\n\n\nDuring this period, 9 cases of fetal goiter were diagnosed on routine ultrasonography with the incidence of 1 in 7,000 live births. The gestation age at diagnosis ranged between 21 weeks and 29 weeks (mean 26 weeks). Of the nine fetuses with goiter, two were excluded as one ended in a miscarriage at 22 weeks and the other was terminated elsewhere at 26 weeks. Data were analyzed in the remaining seven fetuses. Cordocentesis was performed in five fetuses and amniocentesis was performed in one woman with dichorionic diamniotic (DCDA) twin gestation which revealed hypothyroid status. Fetal therapy was offered to all the remaining seven fetuses with intra-amniotic instillation of LT4 100 to 200 μg at 2–3 weeks’ interval. First dose of LT4 was given at mean gestation of 27 weeks (range 23–30 weeks), and the mean time between the identification of fetal goiter and the first dose of LT4 was 6 days (range 2–15 days). Number of injections given ranged between 1 and 7. No adverse events were recorded. Follow-up sonogram showed subjective reduction in the goiter size. All the babies had hypothyroidism at birth.\n\n\n\nOur case series confirms the safety and feasibility of intra-amniotic instillation of LT4 for fetal goitrous hypothyroidism. Although fetal therapy has resulted in reduction in the size of the goiter, the thyroid hormone levels at birth were low. Further research is required to establish the proper management guidelines for this disorder.\n\nBudidapadu M, Vavilala S, Kolar G. Prenatal Diagnosis and Management of Fetal Goiter: A Case Series from Tertiary Perinatal Center in South India. Int J Infertil Fetal Med 2019;10(3):37–41.","PeriodicalId":38998,"journal":{"name":"International Journal of Infertility and Fetal Medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infertility and Fetal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10016-1187","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The reported incidence of fetal goiter is 1 in 40,000 live births. The effects of fetal goiter and thyroid dysfunction are significant. The objective of our study is to assess the safety, feasibility, and efficacy of intra-amniotic instillation of levothyroxine (LT4) in fetal goitrous hypothyroidism. A retrospective observational study of prenatally diagnosed cases of fetal goiter on routine antenatal ultrasound between January 2010 and January 2018 at Fernandez Hospital Foundation, Hyderabad, tertiary perinatal referral center. Data retrieved from electronic database. During this period, 9 cases of fetal goiter were diagnosed on routine ultrasonography with the incidence of 1 in 7,000 live births. The gestation age at diagnosis ranged between 21 weeks and 29 weeks (mean 26 weeks). Of the nine fetuses with goiter, two were excluded as one ended in a miscarriage at 22 weeks and the other was terminated elsewhere at 26 weeks. Data were analyzed in the remaining seven fetuses. Cordocentesis was performed in five fetuses and amniocentesis was performed in one woman with dichorionic diamniotic (DCDA) twin gestation which revealed hypothyroid status. Fetal therapy was offered to all the remaining seven fetuses with intra-amniotic instillation of LT4 100 to 200 μg at 2–3 weeks’ interval. First dose of LT4 was given at mean gestation of 27 weeks (range 23–30 weeks), and the mean time between the identification of fetal goiter and the first dose of LT4 was 6 days (range 2–15 days). Number of injections given ranged between 1 and 7. No adverse events were recorded. Follow-up sonogram showed subjective reduction in the goiter size. All the babies had hypothyroidism at birth. Our case series confirms the safety and feasibility of intra-amniotic instillation of LT4 for fetal goitrous hypothyroidism. Although fetal therapy has resulted in reduction in the size of the goiter, the thyroid hormone levels at birth were low. Further research is required to establish the proper management guidelines for this disorder. Budidapadu M, Vavilala S, Kolar G. Prenatal Diagnosis and Management of Fetal Goiter: A Case Series from Tertiary Perinatal Center in South India. Int J Infertil Fetal Med 2019;10(3):37–41.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
产前诊断和管理胎儿甲状腺肿:一个案例系列从三级围产期中心在印度南部
据报道,胎儿甲状腺肿的发病率为每40000个活产中就有1个。胎儿甲状腺肿和甲状腺功能障碍的影响是显著的。本研究的目的是评估羊膜内滴注左旋甲状腺素(LT4)治疗胎儿甲状腺肿性甲状腺功能减退症的安全性、可行性和有效性。2010年1月至2018年1月,海得拉巴费尔南德斯医院基金会三级围产期转诊中心对产前常规超声诊断为胎儿甲状腺肿的病例进行了回顾性观察研究。从电子数据库检索到的数据。在此期间,常规超声诊断出9例胎儿甲状腺肿,发病率为1/7000。诊断时的妊娠年龄在21周到29周之间(平均26周)。在9个患有甲状腺肿的胎儿中,有两个被排除在外,一个在22周时流产,另一个在26周时终止妊娠。对其余7个胎儿的数据进行了分析。对5名胎儿进行了脐带穿刺,对1名双胎妊娠的妇女进行了羊水穿刺,结果显示甲状腺功能减退。其余7名胎儿均接受胎儿治疗,每隔2-3周在羊膜内滴注100至200μg LT4。第一剂LT4在平均妊娠27周(范围为23–30周)时给药,从胎儿甲状腺肿到第一次给药LT4的平均时间为6天(范围为2–15天)。注射次数在1到7次之间。未记录任何不良事件。随访超声检查显示甲状腺肿大小主观缩小。所有婴儿出生时都患有甲状腺功能减退症。我们的病例系列证实了羊膜内滴注LT4治疗胎儿甲状腺肿性甲状腺功能减退症的安全性和可行性。尽管胎儿治疗使甲状腺肿缩小,但出生时甲状腺激素水平较低。还需要进一步的研究来为这种疾病制定适当的管理指南。Budidapadu M,Vavilala S,Kolar G.胎儿甲状腺肿的产前诊断和处理:来自南印度第三级围产期中心的一系列病例。国际胎儿医学杂志2019;10(3):37–41。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
11
期刊最新文献
Ultrasound Detection of Fetal Structural Anomalies during First Trimester Nuchal Translucency Scan in Conjunction with Traditional 18–22 Weeks Anomaly Scan Impact of Prematuration Culture on Zygote Morphology In Vitro Maturation: An Early Clue to Embryo Competence Fetal Jacob Syndrome (47XYY): An Uncommon Association of Fetal Pulmonary Atresia with Ventricular Septal Defect Occurrence of Insulin Resistance with Recurrent Pregnancy Loss of Unknown Etiology in North Indian Hospital-based Women Population: A Pilot Study POSEIDONE 1 and 2: Probable Causes and Proposed Treatment Strategies? An Evidence-based Update
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1